KR100979077B1 - 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물 - Google Patents

벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물 Download PDF

Info

Publication number
KR100979077B1
KR100979077B1 KR1020047010938A KR20047010938A KR100979077B1 KR 100979077 B1 KR100979077 B1 KR 100979077B1 KR 1020047010938 A KR1020047010938 A KR 1020047010938A KR 20047010938 A KR20047010938 A KR 20047010938A KR 100979077 B1 KR100979077 B1 KR 100979077B1
Authority
KR
South Korea
Prior art keywords
salt
salts
delete delete
alkyl
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047010938A
Other languages
English (en)
Korean (ko)
Other versions
KR20040089106A (ko
Inventor
반데르이르덴요리스에이
드용파울러스피쥐
반데르메이지파울러스에프씨
Original Assignee
솔베이 파마슈티칼스 비. 브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 솔베이 파마슈티칼스 비. 브이 filed Critical 솔베이 파마슈티칼스 비. 브이
Publication of KR20040089106A publication Critical patent/KR20040089106A/ko
Application granted granted Critical
Publication of KR100979077B1 publication Critical patent/KR100979077B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020047010938A 2002-01-16 2003-01-15 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물 Expired - Fee Related KR100979077B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP02075621.9 2002-01-16
EP02075621 2002-01-16
NL1019762 2002-01-17
NL1019762 2002-01-17
PCT/EP2003/000515 WO2003059939A1 (en) 2002-01-16 2003-01-15 Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds

Publications (2)

Publication Number Publication Date
KR20040089106A KR20040089106A (ko) 2004-10-20
KR100979077B1 true KR100979077B1 (ko) 2010-08-31

Family

ID=26077601

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047010938A Expired - Fee Related KR100979077B1 (ko) 2002-01-16 2003-01-15 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물

Country Status (15)

Country Link
US (1) US6998398B2 (enExample)
EP (1) EP1468010A1 (enExample)
JP (1) JP4384495B2 (enExample)
KR (1) KR100979077B1 (enExample)
CN (1) CN100591689C (enExample)
AU (1) AU2003206755B2 (enExample)
BR (1) BR0306701A (enExample)
CA (1) CA2473447A1 (enExample)
HR (1) HRP20040560A2 (enExample)
IL (1) IL162645A0 (enExample)
MX (1) MXPA04006887A (enExample)
NO (1) NO330528B1 (enExample)
PL (1) PL371511A1 (enExample)
RU (1) RU2303041C2 (enExample)
WO (1) WO2003059939A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050009031A (ko) * 2003-07-15 2005-01-24 엘지전자 주식회사 1회 기록 가능한 광디스크 및 광디스크의 관리정보 기록방법
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
AR046454A1 (es) * 2003-11-18 2005-12-07 Solvay Pharm Gmbh Uso de un compuesto de acido benzazepin-n-acetico, composicion farmaceutica, y procedimiento para la produccion de dicha composicion farmaceutica
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
MX2007006279A (es) 2004-12-15 2007-06-14 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
WO2007054975A1 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PL424453A1 (pl) 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783573A (en) * 1996-09-18 1998-07-21 Solvay Pharmaceuticals Gmbh Pharmaceuticals which promote gastrointestinal blood circulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19750002A1 (de) * 1997-11-12 1999-05-20 Solvay Pharm Gmbh Phosphonsäure-substituierte Benzazepinon-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783573A (en) * 1996-09-18 1998-07-21 Solvay Pharmaceuticals Gmbh Pharmaceuticals which promote gastrointestinal blood circulation

Also Published As

Publication number Publication date
EP1468010A1 (en) 2004-10-20
US20050038012A1 (en) 2005-02-17
KR20040089106A (ko) 2004-10-20
CN1617883A (zh) 2005-05-18
AU2003206755B2 (en) 2008-07-17
NO330528B1 (no) 2011-05-09
JP4384495B2 (ja) 2009-12-16
IL162645A0 (en) 2005-11-20
RU2303041C2 (ru) 2007-07-20
US6998398B2 (en) 2006-02-14
CN100591689C (zh) 2010-02-24
HRP20040560A2 (en) 2004-10-31
BR0306701A (pt) 2004-12-28
JP2005520809A (ja) 2005-07-14
RU2004124840A (ru) 2006-01-20
CA2473447A1 (en) 2003-07-24
MXPA04006887A (es) 2004-12-06
PL371511A1 (en) 2005-06-27
NO20043295L (no) 2004-08-06
WO2003059939A1 (en) 2003-07-24
HK1072946A1 (zh) 2005-09-16
AU2003206755A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
US9216947B2 (en) Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
JPH0219363A (ja) イミダゾリジン誘導体
KR100979077B1 (ko) 벤즈아제핀 화합물의 고체 염 및 이를 포함하는 약제학적 조성물
EP2311794B1 (en) Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium polymorphs
JPH0365338B2 (enExample)
JP2004002376A (ja) ５−ヒドロキシ−１−メチルヒダントイン新規結晶形
KR102170422B1 (ko) 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
HUT75341A (en) New salts of 2-[(2,6-dichloro-phenyl)-amino]-phenyl-acetoxy-acetic acid with organic bases, pharmaceutical compns. contg. them and process for preparing the said compds.
TWI284039B (en) Solid salts of benzazepine compounds and their use in the preparation of pharmaceutical compounds
KR840000605B1 (ko) 2-아미노-3-(알킬티오벤조일)-페닐아세트산유도체의 제조방법
ZA200405263B (en) Solid salts benzazepine compounds and their use in the preparation of pharmaceutical compounds.
WO1992007819A1 (fr) Derive de tri(alcoxy inferieur)benzene
CN111138282A (zh) 绿原酸l-精氨酸盐及其用途
HK1072946B (en) Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
HK1137993A (en) Solid salts benzazepine compounds and their use in the preparation of pharmaceuticals compounds
CN110938001A (zh) 绿原酸乙醇胺盐及用途
JPS6348263B2 (enExample)
HK1048059A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20130826

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20130826